ATG16L1 and colorectal carcinoma: Mechanistically, ATG16L1 suppressed type II IFN responses in CRC organoids, and treatment of ATG16L1-deficient cells with a combination of IFNγ and TNF significantly enhanced programmed cell death compared to control CRC organoids.